AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03524612
Drug: eltrombopag
RxNorm normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 12.5, 25, 50 and 75 mg tablets for oral use once daily
Trial: NCT00077779
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04074213
Drug: Clozapine
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine treatment
Trial: NCT02459613
Drug: 99mTc-Annexin V-128 SPECT
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01795703
Drug: Abiraterone
RxNorm normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abiraterone will be administered orally as 1000 milligram (mg) per day for 28-daily dosing cycles which will be continued until disease progression or unacceptable toxicity.
Trial: NCT00147420
Drug: Zhi Byed 11
RxNorm normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04251117
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab administered as an intravenous (IV) infusion
Trial: NCT00652379
Drug: Pegvisomant
RxNorm normalized name: Pegvisomant
DrugBank: Pegvisomant (DB00082)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegvisomant s.c 15-30 mg 2 times a week
Trial: NCT00652379
Drug: Somatostatin analog (lanreotide or octreotide)
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study arm 2: usual dosage of a somatostatin analog Study arm 1: half dosage of somatostatin analog
Trial: NCT03165890
Drug: ACETAZOLAMIDE oral capsule
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
Trial: NCT02370784
Drug: atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin is an oral cholesterol-lowering medication commonly referred to as statin therapy.
Trial: NCT00744887
Drug: Darunavir
RxNorm normalized name: Darunavir
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03112993
Drug: sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: once at the end of the surgery
Trial: NCT03112993
Drug: Neostigmine
RxNorm normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: once at the end of the surgery
Trial: NCT01828515
Drug: Vilazodone
RxNorm normalized name: Vilazodone
DrugBank: Vilazodone (DB06684)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to either vilazodone or placebo titrated as follows: 10 mg x 7 days, 20 mg x 7 days and 40 mg x 5 days.
Trial: NCT00004686
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03443128
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During each course, patients will be treated with vinorelbine (25mg/m2/week on weeks 1-3). After 1 course(4 weeks) of vinorelbine, response will be evaluated by simple assessment: clinical symptoms, signs, B ultrasound, chest X-ray, peripheral blood test and bone marrow smear(if needed). After 2 courses, response will be evaluatedy by simple assessment, CT and FDG-PET. The CR/CRu was defined by anatomic tumour shrinkage more than 75% after 2 courses based on CT with negative PET assessment, with negative bone marrow PCR(if needed) and without CNS involvement. Patients who achieved a CR/CRu after two courses either will proceed to stem cell transplantation (SCT) or will receive additional courses of therapy while awaiting SCT. Response was re-evaluated at the end of every 2 courses. Patients with progressive disease at any time during treatment will be removed from protocol therapy.
Trial: NCT03225664
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT03304418
Drug: Radium Ra 223 Dichloride
RxNorm normalized name: Radium Ra 223 dichloride
DrugBank: Radium Ra 223 dichloride (DB08913)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radium Ra 223 dichloride will be delivered intravenously at 55 kBq/kg (1.49 mCi)/kg (+/- 10% total dose) for a total of six cycles. 1 cycle= 28 days. The first cycle will commence at study enrollment, then cycles 2-6 will commence after the completion of radiotherapies at 4 week intervals
Trial: NCT03937609
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: infliximab iv 5mg/kg
Trial: NCT01236014
Drug: Eltrombopag
RxNorm normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eltrombopag \& standard of care
Trial: NCT01236014
Drug: Romiplostim
RxNorm normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Romiplostim \& standard of care
Trial: NCT02316002
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04227847
Drug: SEA-CD70
RxNorm normalized name: SEA-CD70
DrugBank: SEA-CD70 (DB17555)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle
Trial: NCT04227847
Drug: azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 75mg/m\^2 injected under the skin (SC; subcutaneous) or given into the vein (IV; intravenously) on Days 1 through 7 of each treatment cycle.
Trial: NCT04227847
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400 mg /day PO, continuously; administered with ramping
Trial: NCT03031470
Drug: Reparixin
RxNorm normalized name: Reparixin
DrugBank: Reparixin (DB12614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reparixin was administered as a continuous intravenous infusion for 7 days (Day 0 to Day 6) (168 hours).~Reparixin was provided as 33 mg/ml concentrated solution to be diluted for i.v. infusion, packaged into 250 mL clear glass vials. To give a final concentration of 11 mg/mL, the content of a vial (250 ml) was diluted with 500 ml of 0.9% sterile saline to a total volume of 750 ml. The dosing solution was placed in a 1000 ml sterile empty Infusion Bag. Dosing solutions were to be used within 72 h from preparation, unless more restrictive rules.~Reparixin infusion started approximately 60-90 minutes before the anticipated time of OLT. Infusion interruption was allowed for no more than 60 min.~All patients received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.~Patients and allograft survival were monitored up to 1 year after OLT.
Trial: NCT03053271
Drug: ATR-101
RxNorm normalized name: Atr-101 free base
DrugBank: Nevanimibe (DB16254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the 4-week randomized withdrawal period, subjects will be dosed for 4 weeks at the same dose level being used at the completion of the open-label dose-escalation period.
Trial: NCT04005170
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received toripalimab 240 mg on days 1 and 22 during radiotherapy followed by a maintenance phase of toripalimab IV 240 mg every 3 weeks for up to 1 year.
Trial: NCT04005170
Drug: Paclitaxel/Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received 5 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22, 29 during radiotherapy.
Trial: NCT00666796
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 500 mg oral capsule with 8 oz of water 2 hours prior to assessment timepoint
Trial: NCT01026610
Drug: entecavir 0.5 mg
RxNorm normalized name: entecavir 0.5 MG
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: entecavir 0.5 mg tablet, once daily, for 48 weeks
Trial: NCT02753400
Drug: emixustat hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Emixustat (DB12608)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet for oral administration
Trial: NCT03476356
Drug: oral clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral clomiphene citrate 50 mg tablet, two times per day will be received from the third day of the cycle until the seventh day of the cycle.
Trial: NCT03476356
Drug: oral carnitine supplementation
RxNorm normalized name: carnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral carnitine supplementation 1g tablet, three times per day will be received from the third day of the cycle until the day of the pregnancy test.
Trial: NCT02487823
Drug: BKM120 in combination with LH-RH agonists (suprefact) and bicalutamide
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BKM 120, LH-RH agonists and Bicalutamide
Trial: NCT03507842
Drug: High dose Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: High dose Cytarabine 3.0 g/m2 q12hr 3-hour iv infusion on days 1, 3, 5 plus daunorubicin 45 mg/m2/day continuous iv infusion for 3 days (D1-3).
Trial: NCT03507842
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cytarabine 200 mg/m2/day continuous iv infusion for 7 days (D1-7)
Trial: NCT03507842
Drug: Hign dose Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hign dose Daunorubicin 90 mg/m2/day continuous iv infusion for 3 days (D1-3).
Trial: NCT00918632
Drug: AG-013736
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order A -\> B -\> C. Each of these treatments will be separated by a 7 day washout period.
Trial: NCT00918632
Drug: AG-013736
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order A -\> C -\> B. Each of these treatments will be separated by a 7 day washout period.
Trial: NCT00918632
Drug: AG-013736
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of an FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order B -\> C -\> A. Each of these treatments will be separated by a 7 day washout period.
Trial: NCT00918632
Drug: AG-013736
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order B -\> A -\> C. Each of these treatments will be separated by a 7 day washout period.
Trial: NCT02694523
Drug: risankizumab
RxNorm normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Risankizumab administered by subcutaneous (SC) injection
Trial: NCT00918632
Drug: AG-013736
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order C -\> A -\> B. Each of these treatments will be separated by a 7 day washout period.
Trial: NCT00918632
Drug: AG-013736
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order C -\> B -\> A. Each of these treatments will be separated by a 7 day washout period.
Trial: NCT02694523
Drug: placebo for risankizumab
RxNorm normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo risankizumab administered by subcutaneous (SC) injection
Trial: NCT02594332
Drug: Mepolizumab
RxNorm normalized name: Mepolizumab
DrugBank: Mepolizumab (DB06612)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg SC every 4 weeks for 13 injections
Trial: NCT01671020
Drug: Fimasartan
RxNorm normalized name: Fimasartan
DrugBank: Fimasartan (DB09279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1 fisrt administration of fimasartan 60mg Period 2 second administration of fimasartan 30mg
Trial: NCT01671020
Drug: Fimasartan
RxNorm normalized name: Fimasartan
DrugBank: Fimasartan (DB09279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1 first administration of fimasartan 30mg Period 2 second administration of fimasartan 60mg
Trial: NCT04472143
Drug: Granisetron Transdermal Delivery System
RxNorm normalized name: granisetron Transdermal System
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A total of 60 patients with HER2-positive advanced breast cancer who are scheduled to receive pirotinib combined with capecitabine will be enrolled. A single transdermal patch will be applied to the subject' upper outer arm 24-48 hours before chemotherapy for 7 days. The observation period will be from the time of enrollment to 14 days (± 7 days) after the removal of granisetron patch.
Trial: NCT04455243
Drug: N-Acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg/kg every 12 hours for 14 days (oral/IV) Diluted in 200 ml diluent (D5%, NS)
Trial: NCT01578564
Drug: SOR-C13
RxNorm normalized name: SOR-C13
DrugBank: SOR-C13 (DB15366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous solution for infusion, potential dose range 1.375 mg/kg to 6.12 mg/kg, dosing frequency 2 cycles with a cycle consisting of infusions on days 1-3 and days 8-10 followed by a 11 day off period
Trial: NCT00085228
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00234910
Drug: Tenofovir DF
RxNorm normalized name: LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TDF 300mg QD for 72 wks
Trial: NCT00234910
Drug: lopinavir/ritonavir with 2 Nucleoside RTIs
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: LPV/rSGC 400/100mg BID + 2 nucleoside RTIs as prescribed by the Investigator for 72 wks
Trial: NCT00202176
Drug: Ipratropium Bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized Ipratropium Bromide (4 mL) or saline solution (0.9% NaCl) (4mL) will be administered to subjects once only.
Trial: NCT00237575
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00237575
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00237575
Drug: sargramostim
RxNorm normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00237575
Drug: filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03868852
Drug: Apatinib mesylate tablets
RxNorm normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib mesylate tablets were orally administered 250 mg QD from 1 week before radiotherapy to the whole radiotherapy period. (Appatinib is no longer used after radiotherapy)
Trial: NCT01033526
Drug: Aspirin (Acetylsalicylic acid, BAYE4465)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-2 tablets Acetylsalicylic Acid 400 mg (in combination with Ascorbic Acid 240 mg) as needed every 4-6 hours over a maximum of 5 days
Trial: NCT01022996
Drug: Everolimus (RAD001)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus (RAD001) 10 mg (two 5mg tablets) given orally once daily and packed in blisters.
Trial: NCT03975270
Drug: Sintilimab and Nab-paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sintilimab in Combination with Nab-paclitaxel in Patients with Advanced Recurrent or Metastatic HNSCC after 2 or More Prior Lines of Therapy
Trial: NCT00565591
Drug: Albuterol sulfate
RxNorm normalized name: Albuterol Sulfate
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose dry powder by inhalation
Trial: NCT00931242
Drug: Apremilast
RxNorm normalized name: Apremilast
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Apremilast is being evaluated at daily doses of 20 mg by mouth (PO) twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type Atopic Dermatitis (AD) or Allergic Contact Ddermatitis (ACD).
Trial: NCT00884325
Drug: Levocetirizine dihydrochloride (Xyzal)
RxNorm normalized name: levocetirizine dihydrochloride Oral Tablet [Xyzal]
DrugBank: Levocetirizine (DB06282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One tablet 5 mg taken orally at night for 28 days
Trial: NCT01540825
Drug: BI 113608
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose powder for oral solution
Trial: NCT01540825
Drug: BI 113608
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose powder for oral solution
Trial: NCT01540825
Drug: BI 113608
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose powder for oral solution
Trial: NCT05959603
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Powdered vancomycin will be locally administered once during surgery. The vancomycin will be placed in the surgical bed at several layers: around the hardware and before muscle apposition and above the fascia. This is done before the closure of the muscular fascia and skin by the neurosurgeon. The vancomycin will not be mixed in the bone graft.
Trial: NCT03860987
Drug: goserelin
RxNorm normalized name: Goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin will be administered SC at 10.8 mg every 12 weeks
Trial: NCT03860987
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide will be given orally at 160mg once daily
Trial: NCT03860987
Drug: Abiraterone
RxNorm normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abiraterone will be taken orally at 1000 mg once daily
Trial: NCT03860987
Drug: 18F-DCFPyL
RxNorm normalized name: 18F-DCFPyL
DrugBank: Piflufolastat F 18 (DB14805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F-labeled agent that is a high affinity small molecule inhibitor of PSMA to detect prostate cancer via PET imaging
Trial: NCT02348619
Drug: JZP-110
RxNorm normalized name: JZP-386 free base
DrugBank: JZP-386 free base (DB17068)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01201954
Drug: sucrose
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral sucrose solution, 24%, 0,5 ml/kg, 2 minutes before start the suctioning sterile water, 0,5 ml/kg, 2 minutes before start the suctioning
Trial: NCT03860987
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone will be taken orally at 5mg twice a day for each dose, or 10 mg once a day. Doses should be taken about 12 or 24 hours apart
Trial: NCT03800693
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00276705
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04526106
Drug: RLY-4008
RxNorm normalized name: RLY-2608
DrugBank: RLY-2608 (DB16751)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RLY-4008 is an oral inhibitor of FGFR2
Trial: NCT00276705
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01180166
Drug: nimotuzumab
RxNorm normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 milligram (mg) of nimotuzumab per week during radiation period